Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | aspartyl protease ASP1 | 0.0047 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0121 | 0.2958 | 0.4082 |
Plasmodium falciparum | plasmepsin VI | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0121 | 0.2958 | 0.4082 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0139 | 0.3701 | 0.5108 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0061 | 0.0565 | 0.0107 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.0227 | 0.7246 | 1 |
Plasmodium falciparum | plasmepsin I | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | tachykinin peptides receptor 99D | 0.0296 | 1 | 1 |
Echinococcus granulosus | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Loa Loa (eye worm) | hypothetical protein | 0.0227 | 0.7246 | 1 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.0227 | 0.7246 | 0.7246 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0139 | 0.3701 | 0.5108 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.0227 | 0.7246 | 0.7246 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Schistosoma mansoni | dopamine-beta-monooxygenase | 0.0121 | 0.2958 | 0.4082 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0047 | 0 | 0.5 |
Echinococcus granulosus | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0137 | 0.3598 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0047 | 0 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0137 | 0.3598 | 0.4598 |
Echinococcus multilocularis | cathepsin b | 0.0137 | 0.3598 | 0.3598 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0121 | 0.2958 | 0.365 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0137 | 0.3598 | 0.4965 |
Plasmodium falciparum | plasmepsin II | 0.0047 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0047 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0137 | 0.3598 | 0.4965 |
Plasmodium falciparum | plasmepsin IV | 0.0047 | 0 | 0.5 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0227 | 0.7246 | 1 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0047 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0 | Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 40 mg/kg; no sinificant block 0-25% | ChEMBL. | 6105217 |
Activity (functional) | = 0 | compound was evaluated for its ability to produce catalepsy activity in rats; Dose administered perorally is 50 mg/kg | ChEMBL. | 6105217 |
EDmin (functional) | = 200 mg kg-1 | Hypothermia in mice after perorla administration | ChEMBL. | 6105217 |
EDmin (functional) | = 200 mg kg-1 | Hypothermia in mice after perorla administration | ChEMBL. | 6105217 |
LD50 (ADMET) | > 400 mg kg-1 | Lethal dose in mice after perorla administration | ChEMBL. | 6105217 |
LD50 (ADMET) | > 400 mg kg-1 | Lethal dose in mice after perorla administration | ChEMBL. | 6105217 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.